Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Pheochromocytoma 1Paraganglioma 1Neoplasms, Germ Cell and Embryonal 1Gastrointestinal Stromal Tumors 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 24Cisplatin 18Carboplatin 10Paclitaxel 9Specimen Handling 6Nivolumab 6Doxorubicin 6Docetaxel 6pembrolizumab 5Magnetic Resonance Spectroscopy 5cabozantinib 4avelumab 4Vinblastine 4Radiotherapy 4Methotrexate 4Fluorouracil 4enfortumab vedotin 3atezolizumab 3aflibercept 3Trastuzumab 3Sunitinib 3Ramucirumab 3Platinum 3Ipilimumab 3CTLA-4 Antigen 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3vinflunine 2pegfilgrastim 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urethral Neoplasms × guadecitabine × Genitourinary × Clear all
NCT03179943 2021-11-04

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Fox Chase Cancer Center

Phase 2 Active not recruiting
21 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡